Market Capitalization

With shareholder approval secured, Montage Gold is one step away from acquiring African Gold, a move set to create a new powerhouse in West Africa's gold sector.

A Chinese energy firm is pushing ahead with a Saudi factory, a high-stakes wager that post-conflict rebuilding will outweigh profound geopolitical risks.

After a lengthy legal battle, BGIN Blockchain has recovered 5,325 mining rigs, a move that highlights industry risks and powers its pivot to self-mining.

Payments firm REPAY is doubling down on its $372M KUBRA acquisition, but activist investor Veradace Partners is calling for the deal to be scrapped.

A Chicago jury found Abbott liable for infants' injuries from Similac, adding to a wave of lawsuits over the deadly intestinal disease NEC.

With a $2.135M financing round complete, Golden Shield Resources turns its focus to permitting its promising Marudi Mountain gold project in Guyana.

The passing of Gordon Bowerman, Yangarra's chairman for over two decades, leaves a legacy of growth and a critical question of succession for the company.

TMSH announces a transformative eyewear deal for its subsidiary, but research reveals the vintage brand's focus was apparel just weeks ago.

Mobile game maker DarkIris pivots to an AI-first strategy, launching an R&D hub in Singapore to build a pan-entertainment AGI content platform.

A SPAC deal aims to list one of America's largest lithium resources on NASDAQ, fueling the high-stakes race for domestic battery minerals.

Activist investor Veradace Partners demands Repay scrap its KUBRA deal, alleging a breach of fiduciary duty and widespread shareholder opposition.

The construction tech firm landed on the 2026 USA TODAY Top Workplaces list. We explore the employee-driven data and culture that set it apart.

As Crocs sets its Q1 earnings call, all eyes are on the struggling HEYDUDE brand, contrasting with the core brand's strong international performance.

ADP's latest dividend declaration highlights its financial strength and commitment to shareholders, cementing its status as a reliable income-generating stock.

As online reviews face a crisis of trust, a Bay Area company doubles down on a physical directory, betting that verified quality is worth its weight in paper.

After three rejections, Outlook Therapeutics escalates its fight for US approval of a key wet AMD drug, already sold in Europe. Will the FDA bend?

With its lead cancer drug advancing and a strong balance sheet, Nurix will detail its vision for protein degradation at a key investor conference.

Computing power operator SAIHEAT is shifting its nuclear strategy from building reactors to selling design software, a bold move into a competitive market.

A new report reveals a major education gap in obesity care. Informed patients are now demanding options beyond blockbuster drugs like Wegovy and Zepbound.

A new award-winning serum promises 'glass skin' and enhances injectable results, tapping into a multi-billion dollar market. Here's the science behind it.